当前位置： SCI文献检索 > LEUKEMIA RESEARCH期刊下所有文献 > Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.

Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.

Abstract：

:Hypereosinophilic syndrome (HES) is characterized by sustained non-clonal blood and tissue eosinophilia, leading to end-organ damage. With a molecular/cytogenetic clonality marker, the disease is classified as chronic eosinophilic leukemia (CEL). Efficacy of imatinib mesylate is well established in CEL with FIP1L1-platelet-derived growth factor-alpha (PDGFRalpha) rearrangement. We treated with imatinib 18 HES patients (11 PDGFRalpha-negative and 7 PDGFRalpha-status unknown). One patient with unknown PDGFRalpha status achieved complete hematologic response, and two (one PDGFRalpha negative and one status unknown) achieved partial hematologic response. Our results confirm low response rate to imatinib in HES patients with unknown or negative PDGFRalpha status, and underscore the need for new therapeutic options for this disorder.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Jain N,Cortes J,Quintás-Cardama A,Manshouri T,Luthra R,Garcia-Manero G,Kantarjian H,Verstovsek S

doi

10.1016/j.leukres.2008.10.004

subject

Has Abstract

pub_date

2009-06-01 00:00:00

pages

837-9

issue

6

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(08)00464-5

journal_volume

33

pub_type

杂志文章

相关文献

LEUKEMIA RESEARCH文献大全
  • Constitutional trisomy 8 and myelodysplasia: report of a case and review of the literature.

    abstract：:A diagnosis of myelodysplastic syndrome was made in an 18-year-old patient with Warkany syndrome due to constitutional trisomy 8 mosaicism. The possible causal role of this particular chromosome constitution with respect to myelodysplasia and embryonal childhood tumors is discussed. ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(95)00050-x

    authors： Zollino M,Genuardi M,Bajer J,Tornesello A,Mastrangelo S,Zampino G,Mastrangelo R,Neri G

    更新日期：1995-10-01 00:00:00

  • International Working Group on MDS cytogenetics: October 2007 meeting report.

    abstract：:The inaugural meeting of the International Working Group on MDS cytogenetics convened 22-23 October 2007 in Chicago, IL. Under the sponsorship of the Myelodysplastic Syndromes Foundation, the group was organized to address the substantial need for worldwide standardized cytogenetic testing for MDS in clinical practice...

    journal_title：Leukemia research

    pub_type： 总体

    doi：10.1016/j.leukres.2008.03.009

    authors： Slovak ML,Dewald GW,International Working Group on MDS cytogenetics.

    更新日期：2008-09-01 00:00:00

  • Deoxycytidylate deaminase activity in lymphoproliferative disorders.

    abstract：:The activity of dCMPase has been measured in cell extracts from human lymphoproliferative disorders. The highest levels occurred in T helper-CLL and Thy-ALL, but high levels were also found in C-ALL, NPDLL transforming to DHL, DPDLL and DHL. A range of enzyme activities was found in the majority of types examined, wit...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(84)90040-7

    authors： Ellims PH,Medley G

    更新日期：1984-01-01 00:00:00

  • Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience.

    abstract：OBJECTIVE:Bortezomib-dexamethasone-thalidomide has been reported to be effective in newly-diagnosed multiple myeloma (MM) with an overall response rate of 92% and a CR rate of 18% (Alexanian et al, Hematology 2007;12(3):235-9), but this regimen has not been tested in the Chinese patients. We report here our results tes...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.04.006

    authors： Zheng W,Wei G,Ye X,He J,Li L,Wu W,Shi J,Zhang J,Huang W,Xie W,Luo Y,Xue X,Lin M,Huang H,Cai Z

    更新日期：2009-12-01 00:00:00

  • Hierarchical regulation of interleukin production: induction of interleukin 6 (IL-6) production from bone marrow cells and marrow stromal cells by interleukin 3 (IL-3).

    abstract：:IL-3 stimulated the production of IL-6 from a bone marrow-adherent cell population, macrophages and from hemopoietic supportive stromal cell lines. It also induced IL-6 production from a stem cell-enriched population of bone marrow cells which did not produce IL-6 without stimulation. In contrast, stimulation with IL-...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(91)90180-2

    authors： Miyashita M,Sugimoto K,Suzuki J,Taniguchi S,Aramaki K,Mori KJ

    更新日期：1991-01-01 00:00:00

  • Transcriptional deregulation of homeobox gene ZHX2 in Hodgkin lymphoma.

    abstract：:Recently, we identified a novel chromosomal rearrangement in Hodgkin lymphoma (HL), t(4;8)(q27;q24), which targets homeobox gene ZHX2 at the recurrent breakpoint 8q24. This aberration deletes the far upstream region of ZHX2 and results in silenced transcription pinpointing loss of activatory elements. Here, we have lo...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2011.10.019

    authors： Nagel S,Schneider B,Meyer C,Kaufmann M,Drexler HG,Macleod RA

    更新日期：2012-05-01 00:00:00

  • 5'-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells.

    abstract：:Imatinib is a highly effective drug for the treatment of chronic myeloid leukemia (CML) that targets the BCR-ABL kinase. However, a number of patients have CML that is resistant to Imatinib treatment. In this report, we developed AGM130 as a potential therapeutic drug for Imatinib-resistant CML treatment. The AGM130 c...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.12.017

    authors： Kim WS,Lee MJ,Kim DH,Lee JE,Kim JI,Kim YC,Song MR,Park SG

    更新日期：2013-04-01 00:00:00

  • Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).

    abstract：:Homoharringtonine combined aclarubicin and cytarabine (HAA) has been demonstrated to achieve a high remission rate and provide a survival advantage in acute myeloid leukemia (AML). To investigate whether HAA is an ideal induction regimen for t(8;21)AML, we retrospectively analyzed the data of 140 patients from the las...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2016.02.012

    authors： Zhu HH,Jiang H,Jiang Q,Jia JS,Qin YZ,Huang XJ

    更新日期：2016-05-01 00:00:00

  • Transcriptional profiling and assessment of cell lines as in vitro models for mantle cell lymphoma.

    abstract：:Mantle cell lymphoma (MCL) is an aggressive malignancy and new treatment modalities must be established to increase patient survival time. In the search for new therapeutic targets, reliable and well-characterised in vitro models are essential. In this study, we have characterised three MCL cell lines (SP53, Granta 51...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2004.06.009

    authors： Ek S,Ortega E,Borrebaeck CA

    更新日期：2005-02-01 00:00:00

  • Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico.

    abstract：:This study evaluated the association of -401C/T and +452C/T polymorphisms of gamma-glutamyl hydrolase and the risk of relapse to acute lymphoblastic leukemia. Genotyping was performed in 70 children with acute lymphoblastic leukemia and 140 healthy children. An association between the -401C/T polymorphism and the risk...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.11.027

    authors： Organista-Nava J,Gómez-Gómez Y,Saavedra-Herrera MV,Rivera-Ramírez AB,Terán-Porcayo MA,Alarcón-Romero Ldel C,Illades-Aguiar B,Leyva-Vázquez MA

    更新日期：2010-06-01 00:00:00

  • Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.

    abstract：:Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients who are resistant to imatinib are commonly treated with second-generation tyrosine kinase inhibitors (TKIs). Limited data exist on the possible effects of these drugs on subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT).The outco...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2009.04.036

    authors： Breccia M,Palandri F,Iori AP,Colaci E,Latagliata R,Castagnetti F,Torelli GF,Usai S,Valle V,Martinelli G,Rosti G,Foà R,Baccarani M,Alimena G

    更新日期：2010-02-01 00:00:00

  • Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors.

    abstract：:We examined the effect of deferasirox (DFX) on CD34+ hematopoietic progenitors from MDS patients. Progressive, dose-dependent suppression of MDS progenitor proliferation in culture was observed with DFX concentrations ranging from 5 μM to 20 μM. This effect was more pronounced in MDS compared to CD34+ progenitors isol...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.03.018

    authors： Pullarkat V,Sehgal A,Li L,Meng Z,Lin A,Forman S,Bhatia R

    更新日期：2012-08-01 00:00:00

  • Neuroleukin mediated differentiation induction of myelogenous leukemia cells.

    abstract：:Leukemia cells enriched from peripheral blood of a patient with myelogenous leukemia were induced to differentiate with a purified T cell lymphokine neuroleukin. With sufficient neuroleukin concentrations, cells with macrophage-like morphology were identified among the developing adherent cells. After 2-5 days, approx...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(98)00129-5

    authors： Chiao JW,Xu W,Seiter K,Feldman E,Ahmed T

    更新日期：1999-01-01 00:00:00

  • Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance.

    abstract：:The ubiquitin-proteasome system (UPS) plays a major role in the homeostasis of cellular protein. We demonstrate that each of the major hematologic diseases (AML, ALL, and MDS) has a specific and different plasma profile of UPS protein and enzymatic activities. While high levels of proteasome and ubiquitin proteins and...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2010.09.009

    authors： Ma W,Kantarjian H,Zhang X,Wang X,Estrov Z,O'Brien S,Albitar M

    更新日期：2011-04-01 00:00:00

  • The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia.

    abstract：:A clonal origin of hematopoiesis was studied by investigation of X-chromosome inactivation patterns (XCIP) in isolated granulocyte, CD14(+) and CD3(+) subpopulations obtained from bone marrow and peripheral blood of 36 female patients with primary myelodysplastic syndrome (MDS). Clonality was assessed by PCR amplifica...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2004.08.008

    authors： Cermák J,Belicková M,Krejcová H,Michalová K,Zilovcová S,Zemanová Z,Brezinová J,Sieglová Z

    更新日期：2005-04-01 00:00:00

  • PDTC enables type I TRAIL signaling in type II follicular lymphoma cells.

    abstract：:Based on Bcl-X(L) overexpression studies we identified type I and type II follicular lymphoma cell lines in response to TRAIL. We demonstrate here that either amount of caspase-8 activation or Bid cleavage could not define the dependence on mitochondria. Furthermore, an inhibitor of NF-kappaB, PDTC, enabled TRAIL to a...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.09.025

    authors： Nuutinen U,Simelius N,Ropponen A,Eeva J,Mättö M,Eray M,Pellinen R,Wahlfors J,Pelkonen J

    更新日期：2009-06-01 00:00:00

  • Acute myeloid leukemia with hypergranular cytoplasm accompanied by t(X;11)(q24;q23) and rearrangement of the MLL gene.

    abstract：:This report describes a unique case of acute myeloid leukemia with hypergranular cytoplasm and t(X;11)(q24;q23). The breakpoint on 11q23 was identified within the MLL gene. The hypergranular cytoplasm of leukemic cells and the associated coagulopathy resembled a characteristic of acute promyelocytic leukemia, despite ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(98)00131-3

    authors： Nakata Y,Mori T,Yamazaki T,Suzuki T,Okazaki T,Kurosawa Y,Kinoshita A,Ohyashiki K,Nakazawa S

    更新日期：1999-01-01 00:00:00

  • ER stress in diffuse large B cell lymphoma: GRP94 is a possible biomarker in germinal center versus activated B-cell type.

    abstract：:The process of B-cell development is characterized by the activation of the unfolded protein response. Under certain circumstances, the unfolded protein response can be manipulated in a cell death-inducing way. Therefore, tackling the unfolded protein response might be an attractive strategy in the treatment of diffus...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2012.08.017

    authors： Boelens J,Jais JP,Vanhoecke B,Beck I,Van Melckebeke H,Philippé J,Bracke M,Jardin F,Brière J,Leroy K,Offner F,Lust S

    更新日期：2013-01-01 00:00:00

  • The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML).

    abstract：:We retrospectively evaluated the prognostic significance of polypharmacy and inappropriate medication use among 150 patients >60 years of age receiving induction chemotherapy for acute myelogenous leukemia (AML). After adjustment for age and comorbidity, increased number of medications at diagnosis (≥ 4 versus ≤ 1) wa...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2014.06.018

    authors： Elliot K,Tooze JA,Geller R,Powell BL,Pardee TS,Ritchie E,Kennedy L,Callahan KE,Klepin HD

    更新日期：2014-10-01 00:00:00

  • Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.

    abstract：:The impact of genetic aberrations on rituximab-based therapeutic regimens has been intensely studied in chronic lymphocytic leukemia (CLL). According to the current consensus chemoimmunotherapy consisting of rituximab and DNA-damaging drugs is not suitable for patients with TP53 defects. In our study, we focused on CL...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2019.04.015

    authors： Spunarova M,Tom N,Pavlova S,Mraz M,Brychtova Y,Doubek M,Panovska A,Skuhrova Francova H,Brzobohata A,Pospisilova S,Mayer J,Trbusek M

    更新日期：2019-06-01 00:00:00

  • Human B-cell lymphoma cell lines are highly sensitive to apoptosis induced by all-trans retinoic acid and interferon-gamma.

    abstract：:When cells were incubated in the presence of both interferon-gamma (IFN-gamma) and all-trans retinoic acid (ATRA), the concentration of IFN-gamma required to induce apoptosis of B-cell lymphoma cells was much lower than that required for myeloid or erythroid cell lines. The concentration of IFN-gamma that effectively ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(01)00202-8

    authors： Niitsu N,Higashihara M,Honma Y

    更新日期：2002-08-01 00:00:00

  • Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature.

    abstract：:Our retrospective analysis explored the role of leukemia cutis (LC) in disease progression of chronic myelomonocytic leukemia (CMML). Of 108 patients with CMML, 11 patients (10.2%) had LC including its equivalent (2 patients). Four of these patients developed acute myeloid leukemia (AML) within 0-4 months. The remaini...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2011.05.003

    authors： Mathew RA,Bennett JM,Liu JJ,Komrokji RS,Lancet JE,Naghashpour M,Messina JL,List AF,Moscinski LC,Zhang L

    更新日期：2012-01-01 00:00:00

  • Temporary blast reduction after immunoglobulin administration for congenital cytomegalovirus infection masking infant leukemia with cryptic MLL rearrangement.

    abstract：:Differentiation between reactive bone marrow suppression due to viral infection and early stages of leukemia can be difficult particularly in young infants. We report on a 2-month-old girl presenting with pancytopenia and positive markers for congenital cytomegalovirus (CMV) infection. Definitive diagnosis of coexisti...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2006.05.020

    authors： Metzler M,Bruch J,Stachel D,Langer T,Borkhardt A,Harbott J,Rascher W,Holter W

    更新日期：2007-04-01 00:00:00

  • Is cigarette smoking a risk factor for non-Hodgkin's lymphoma or multiple myeloma? Results from the Lutheran Brotherhood Cohort Study.

    abstract：:Among 17,633 U.S. white male insurance policy holders whose use of tobacco was characterized in a 1966 self-administered questionnaire, there were 49 deaths from non-Hodgkin's lymphoma (NHL) and 21 from multiple myeloma (MM) during a 20-year follow-up. Men who had ever smoked cigarettes had an elevated mortality from ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(92)90011-u

    authors： Linet MS,McLaughlin JK,Hsing AW,Wacholder S,Co Chien HT,Schuman LM,Bjelke E,Blot WJ

    更新日期：1992-06-01 00:00:00

  • Clinical consequences of 2'-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia.

    abstract：:Five patients from the Kyushu area in Japan with adult T-cell leukaemia (ATL) refractory to conventional chemotherapeutic agents were treated with 5 mg/m2 of the adenosine deaminase inhibitor, 2'-deoxycoformycin (DCF), intravenously (i.v.) for 3 consecutive days, followed by 5 mg/m2 i.v. weekly. Two patients showed a ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(86)90251-1

    authors： Yamaguchi K,Yul LS,Oda T,Maeda Y,Ishii M,Fujita K,Kagiyama S,Nagai K,Suzuki H,Takatsuki K

    更新日期：1986-01-01 00:00:00

  • Variations of the phosphorylation of 1-beta-D-arabinofuranosylcytosine (ARA-C) in human myeloid leukemic cells related to the cell cycle.

    abstract：:Bone marrow cells of five patients with acute myeloid leukemia were fractionated by means of counterflow centrifugation (elutriation). The different fractions were enriched with cells belonging to subsequent stages of the cell cycle. Cytokinetic evaluation of these cell fractions was performed by [3H]thymidine autorad...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(82)90031-5

    authors： Vierwinden G,Drenthe-Schonk AM,Plas AM,Linssen PC,Pennings AH,Holdrinet RS,van Egmond J,Wessels JM,Haanen CA

    更新日期：1982-01-01 00:00:00

  • Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients.

    abstract：:Limited information is available on the relationship between expression of some additional aberrant phenotypic features and outcome of acute promyelocytic leukemia (APL) patients. Here, we set out to assess the frequency of CD15 and CD56 expression, and their prognostic value in a large series of APL patients. One hun...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2013.11.008

    authors： Breccia M,De Propris MS,Minotti C,Stefanizzi C,Raponi S,Colafigli G,Latagliata R,Guarini A,Foà R

    更新日期：2014-02-01 00:00:00

  • Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS.

    abstract：:Clinical features of myelodysplastic syndromes (MDS) could be influenced by many factors, such as disease intrinsic factors (e.g., morphologic, cytogenetic, molecular), extrinsic factors (e.g, management, environment), and ethnicity. Several previous studies have suggested such differences between Asian and European/U...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/j.leukres.2018.08.022

    authors： Miyazaki Y,Tuechler H,Sanz G,Schanz J,Garcia-Manero G,Solé F,Bennett JM,Bowen D,Fenaux P,Dreyfus F,Kantarjian H,Kuendgen A,Malcovati L,Cazzola M,Cermak J,Fonatsch C,Le Beau MM,Slovak ML,Santini V,Lübbert M,Macieje

    更新日期：2018-10-01 00:00:00

  • Alterations of HLe-1 (T200) fluorescence intensity on acute lymphoblastic leukemia cells may relate to therapeutic outcome.

    abstract：:Quantitative differences in HLe-1 expression were studied on normal lymphocytes and lymphoblasts of patients with acute lymphoblastic leukemia (ALL). A relationship was found between quantitative antigen expression and therapeutic outcome. Alterations in fluorescence intensity (FI) were demonstrated using quantitative...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(87)90110-x

    authors： Caldwell CW,Patterson WP,Hakami N

    更新日期：1987-01-01 00:00:00

  • Angiogenic factors in chronic lymphocytic leukemia.

    abstract：:Angiogenesis is a complex process controlled by the balance of a large number of regulating factors, the pro- and anti-angiogenic factors. Dysregulation of angiogenesis occurs in various pathologies and is one of the hallmarks for cancer. Recent emphasis on the microenvironment's influence in chronic lymphocytic leuke...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2012.05.021

    authors： Xia Y,Lu RN,Li J

    更新日期：2012-10-01 00:00:00